Regression of femoral atherosclerosis.
Author(s) -
Anders Olsson
Publication year - 1991
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/01.cir.83.2.698
Subject(s) - medicine , arteriosclerosis , coronary atherosclerosis , cardiology , coronary artery disease , aorta
T he scientific community has by now generally accepted that human atherosclerosis development can be influenced by therapeutic means. This insight has mainly been based on studies of the coronary arteries, the conclusive one being the Cholesterol Lowering Atherosclerosis Study (CLAS)1 but supported by studies like the National Heart, Lung, and Blood Institute (NHLBI) study,2 the Helsinki Coronary Study,3 the Leiden Intervention Trial,4 the recently published Lifestyle Heart Trial,5 the Program on the Surgical Control of the Hyperlipidemias (POSCH),6and the FamilialAtherosclerosisTreatment Study (FATS).7 Atheroma change was estimated by expert panels in all these studies except the FATS, in which a computer-assisted visual system was used,8 and the Lifestyle Heart Trial. Treatment has in all these instances been by plasma lipid regulation. Recently one study was published on the effect of the calcium-channel blocker nifedipine on coronary atherosclerosis progression.9
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom